Chronic Myeloid Leukemia Clinical Trial
Official title:
Retro-prospective Observational Study on Risk of Progression in Chronic Phase-Chronic Myeloid Leukemia Patients Eligible for Tyrosine Kinase Inhibitor Discontinuation (TFR - PRO)
The purpose of this study is to investigate the safety profile of TKI discontinuation in clinical practice, with particular regard on the risk of progression after treatment discontinuation.
Status | Recruiting |
Enrollment | 3000 |
Est. completion date | September 30, 2023 |
Est. primary completion date | September 30, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Signed and dated IRB/IEC-approved informed consent for the prospective cohort patients. 2. Age >= 18 years. 3. Male or female patients with CML diagnosed in chronic phase (CP). 4. At least 4 years of TKI treatment. 5. At least 18 months of DMR. Exclusion Criteria: - Allogeneic hematopoietic stem cell transplantation. - CML diagnosed in AP or BC |
Country | Name | City | State |
---|---|---|---|
Canada | McGill University - Jewish General Hospital Division of Hematology and Department of Oncology | Montréal | Quebec |
Germany | Charité University of Berlin - Clinic of Medicine - Hematology and Oncology | Berlin | |
Germany | University of Mannheim, Mannheim, Germania | Mannheim | |
Italy | Istituto di Ematologia "Lorenzo e A. Seragnoli" Policlinico S. Orsola Malpighi, | Bologna | |
Italy | CTMO Ematologia Ospedale "Businco" | Cagliari | |
Italy | Università di Catania Cattedra di Ematologia Ospedale "Ferrarotto" | Catania | |
Italy | SOC Ematologia Az. Ospedaliera Pugliese Ciaccio (AOPC) | Catanzaro | |
Italy | Ematologia Ospedale Cuneo | Cuneo | |
Italy | UO Ematologia O spedale Milano S. Raffaele | Miano | |
Italy | Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico UOC di Ematologia | Milano | Italy/Milano |
Italy | ASST-Monza | Monza | Italy/MB |
Italy | Azienda Ospedaliera di Rilievo Nazionale "A. Cardarelli" | Napoli | |
Italy | Azienda Ospedaliera Universitaria Università degli Studi di Napoli "Federico II" Facoltà di Medicina e Chirurgia | Napoli | |
Italy | U.O. di Ematologia con trapianto A.U. Policlinico "Paolo Giaccone" | Palermo | |
Italy | Unità operativa Ematologia e CTMO Az Ospedaliera Universitaria | Parma | |
Italy | Fondazione IRCCS Policlinico San Matteo | Pavia | |
Italy | Università di Pisa Azienda Ospedaliera Pisana Divisione di Ematologia | Pisa | |
Italy | Azienda Unità Sanitaria Locale IRCCS | Reggio Emilia | |
Italy | Universita di Tor Vergata Ospedale S. Eugenio | Rome | Italy/Rome |
Italy | Dipartimento di Oncologia ed Ematologia S.C. Ematologia 2 A.O. Città della Salute e della Scienza di Torino S. G.Battista | Torino | |
Italy | Struttura Complessa a Dir. Universitaria Ematologia e Terapie Cellulari A.S.O. Ordine Mauriziano, P.O. U mberto I | Torino | |
Italy | S.C. Ematologia, Ospedale di Circolo e Fondazione Macchi Varese, ASST dei Sette Laghi, | Varese | |
Italy | U.O. di Ematologia Ospedale dell'Angelo Mestre | Venezia | |
Italy | Istituti Ospitalieri di Verona Div. di Ematologia Policlinico G.B. Rossi | Verona | |
Italy | U.O. Complessa di Ematologia Azienda ULSS 8 "Berica" Ospedale San Bortolo | Vicenza | |
Spain | University Hospital Clínic de Barcelona | Barcelona |
Lead Sponsor | Collaborator |
---|---|
University of Milano Bicocca |
Canada, Germany, Italy, Spain,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The quantification of the risk of progression | To quantify the risk of progression to accelerated phase (AP) or blast phase (BP), expressed as time adjusted rate (TAR), after TKI discontinuation in CML patients who undergo a first or subsequent TKI discontinuation attempt | 36 Month | |
Secondary | To compare the time adjusted rate (TAR) of progression from Chronic phase-Chronic Myeloid Leukemia to Accelerated phase (AP) or Blastic phase (BP) by using the percentage of blasts, promyelocytes, basophils or platelet in blood or bone marrow | To compare the TAR (time adjusted rate) of progression to AP or BP that is obtained in the target population to that obtained in a similar population of patients with the same characteristics who do not discontinue TKI treatment | 36 Month | |
Secondary | Progression free survival (PFS) after TKI discontinuation. | PFS will be defined as time between discontinuation and progression to AP or BP. | 36 Month | |
Secondary | Rate of molecular relapse (loss of MR3 or MMR) | Rate of molecular relapse (loss of MR3 or MMR) at 12 and 24 months after TKI discontinuation. | 36 Month | |
Secondary | Relapse free survival (RFS) after TKI discontinuation. | Relapse free survival (RFS) after TKI discontinuation. RFS will be defined as time between discontinuation and loss of MMR (i.e. molecular relapse). | 36 Month | |
Secondary | Percentage of relapsed patients who obtain a new deep molecular response (DMR) within 6-12 months of treatment resumption among all patients who restart TKI treatment because of a molecular relapse after TKI discontinuation. | The following criteria will be used to define DMR (43):
MR4 = either (i) detectable disease with <0.01% BCR-ABL1IS or (ii) undetectable disease in cDNA with >10 000 ABL1 transcripts. MR4.5 = either (i) detectable disease with <0.0032% BCR-ABL1IS or (ii) undetectable disease in cDNA with >32 000 ABL1 transcripts in the same volume of cDNA used to test for BCR-ABL1. MR5 = either (i) detectable disease with <0.001% BCR-ABL1IS or (ii) undetectable disease in cDNA with >100 000 ABL1 transcripts in the same volume of cDNA used to test for BCR-ABL1. |
36 Month |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05400122 -
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
|
Phase 1 | |
Completed |
NCT02057185 -
Occupational Status and Hematological Disease
|
||
Recruiting |
NCT03326310 -
Selumetinib and Azacitidine in High Risk Chronic Blood Cancers
|
Phase 1 | |
Completed |
NCT01207440 -
Ponatinib for Chronic Myeloid Leukemia (CML) Evaluation and Ph+ Acute Lymphoblastic Leukemia (ALL)
|
Phase 2 | |
Not yet recruiting |
NCT06409936 -
PEARL Study: PotEntial of Asciminib in the eaRly Treatment of CML
|
Phase 2 | |
Active, not recruiting |
NCT02917720 -
2nd or 3rd TKI-stop After 2 Years Nilotinib Pre-treatment in CML-patients
|
Phase 2 | |
Not yet recruiting |
NCT02883036 -
Vitro Study of Tigecycline to Treat Chronic Myeloid Leukemia
|
N/A | |
Withdrawn |
NCT01188889 -
RAD001 in Patients With Chronic Phase Chronic Myeloid Leukemia w/ Molecular Disease.
|
Phase 1/Phase 2 | |
Completed |
NCT01795716 -
Bioequivalence Study of Mesylate Imatinib Capsule in Chronic Myeloid Leukemia Body
|
Phase 1 | |
Completed |
NCT00988013 -
Intensity Modulated Total Marrow Irradiation (IM-TMI) for Advanced Hematologic Malignancies
|
N/A | |
Approved for marketing |
NCT00905593 -
Nilotinib in Adult Patients With Imatinib-resistant or Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase
|
Phase 3 | |
Terminated |
NCT00573378 -
Imatinib or Nilotinib With Pegylated Interferon-α2b in Chronic Myeloid Leukemia
|
Phase 2 | |
Completed |
NCT00469014 -
Busulfan, Fludarabine, Clofarabine With Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia
|
Phase 2 | |
Terminated |
NCT00522990 -
Study to Assess the Safety of Escalating Doses of AT9283, in Patients With Leukemias
|
Phase 1/Phase 2 | |
Unknown status |
NCT00598624 -
Clinical Trial to Evaluate the Safety and Efficacy of Treosulfan Based Conditioning Prior to Allogeneic Haematopoietic Stem Cell Transplantation (HSCT)
|
Phase 2 | |
Completed |
NCT00257647 -
Use of SV40 Vectors to Treat Chronic Myeloid Leukemia (CML)
|
N/A | |
Completed |
NCT00219739 -
STI571 ProspectIve RandomIzed Trial: SPIRIT
|
Phase 3 | |
Completed |
NCT06148493 -
Real-World Usage of Asciminib Among Patients With Chronic Myeloid Leukemia in Chronic Phase in the United States Using a Large Claims Database
|
||
Completed |
NCT00375219 -
Homoharringtonine (Omacetaxine Mepesuccinate) in Treating Patients With Chronic Myeloid Leukemia (CML) With the T315I BCR-ABL Gene Mutation
|
Phase 2 | |
Completed |
NCT04605211 -
A Distress Reduction Intervention for Patients With BCR-ABL-Negative MPNs or CML on Tyrosine Kinase Inhibitors
|
N/A |